

PTO/SB/21 (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/802,427
Filing Date	March 17, 2004
First Named Inventor	Gustavo C. Rodriguez
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	31162A

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. 105 References 2. Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Jenner & Block		
Signature			
Printed name	Raymond N. Nimrod		
Date	August 2, 2006	Reg. No.	31,987

CERTIFICATE OF TRANSMISSION/MAILING


I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Robin L. Ustaniuk	Date	August 2, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./



08-04-06

1FW 15

PTO/SB/17 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.

Transmitted to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2005☒ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$) 180.00**Complete if Known**

Application Number	10/802,427
Filing Date	March 17, 2004
First Named Inventor	Gustavo C. Rodriguez
Examiner Name	Raymond J. Henley III
Art Unit	1614
Attorney Docket No.	31162A

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 10-0460 Deposit Account Name: Jenner & Block LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee
☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180
Total Claims	Extra Claims	Fee (\$)
- 20 or HP = _____ x _____ = _____		
HP = highest number of total claims paid for, if greater than 20.		
Indep. Claims	Extra Claims	Fee (\$)
- 3 or HP = _____ x _____ = _____		
HP = highest number of independent claims paid for, if greater than 3.		

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____				

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)	Fees Paid (\$)
Other (e.g., late filing surcharge): Information Disclosure Statement	180.00


SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 31,987	Telephone 312-923-8306
Name (Print/Type)	Raymond N. Nimrod		Date August 2, 2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./



CERTIFICATE OF EXPRESS MAIL UNDER 37 CFR 1.10

"Express Mail" Label No. EQ478121444US

Date August 2, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" Post Office to addressees" on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robin Ustanik
(signature)

Robin Ustanik
(typed/printed name)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rodriguez, et al.)
Application No.: 10/802,427) Examiner: Raymond J. Henley III
Filing Date: March 17, 2004) Group Art Unit: 1614
Title: Prevention Of Ovarian Cancer By)
Administration Of Products That Induce)
Biologic Effects In The Ovarian Epithelium)

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. 1.97 and 1.98, and in compliance with 37 C.F.R. 1.56, the Office's attention is directed to the references listed on the attached PTO-1449 forms. A copy of each of the listed documents is enclosed.


The Commissioner is hereby authorized to charge any the fee of \$180 prescribed in 37 C.F.R. § 1.17(p) and any additional fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 10-0460.

08/04/2006 HDESTA1 00000082 100460 10802427

01 FC:1806 180.00 DA

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./


Respectfully submitted,



Raymond N. Nimrod
Registration No. 31,987

Jenner & Block LLP
One IBM Plaza
Chicago, IL 60611
Ph. (312) 927-5833
Fax (312) 923-8406

Date: August 2, 2006



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known

Application Number	10/802,427
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	31162A

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 3,957,982	05-18-1976	Lachnit-Fixson et al.	
		US- 3,969,502	07-13-1976	Lachnit-Fixson	
		US- 4,390,531	06-28-1983	Edgren	
		US- 4,530,839	07-23-1985	Pasquale	
		US- 4,544,554	10-01-1985	Pasquale	
		US- 4,616,006	10-07-1986	Pasquale	
		US- 4,621,079	11-04-1986	Lachnit-Fixson et al.	
		US- 4,628,051	12-09-1986	Pasquale	
		US- 4,760,053	07-26-1988	Labrie	
		US- 4,817,819	04-04-1989	Kelly	
		US- 4,833,125	05-23-1989	Neer	
		US- 4,855,305	08-08-1989	Cohen	
		US- 4,906,169	03-06-1990	Chien	
		US- 4,921,843	05-01-1990	Pasquale	
		US- 4,962,098	10-09-1990	Boissonneault	
		US- 5,108,995	04-28-1992	Casper	
		US- 5,256,421	10-26-1993	Casper	
		US- 5,262,408	11-16-1993	Bergink	
		US- 5,280,023	01-18-1994	Ehrlich et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 0 253 607 A1	01-20-1988	Upton		
		EP 0 253 607 B1	01-20-1988	Upton		
		EP 0 628 312 B1	12-14-1994	Wablat		
		WO 95/26730 A1	10-12-1995	Schering		
		WO 97/11680	04-03-1997	Elliesen		
		WO 98/10771 A1	03-19-1998	Rodriguez		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 8

Complete if Known

Application Number	10/802,427
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	31162A

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,314,694	05-24-1994	Gale et al.	
		US- 5,382,573	01-17-1995	Casper	
		US- 5,416,091	05-16-1995	King	
		US- 5,418,228	05-23-1995	Bennink	
		US- 5,422,119	06-06-1995	Casper	
		US- 5,461,041	10-24-1995	Bergink et al.	
		US- 5,468,736	11-21-1995	Hodgen	
		US- 5,552,394	09-03-1996	Hodgen	
		US- 5,583,129	12-10-1996	Spona et al.	
		US- 5,595,970	01-21-1997	Garfield et al.	
		US- 5,620,705	04-15-1997	Dong et al.	
		US- 5,633,011	05-27-1997	Dong et al.	
		US- 5,747,480	05-05-1998	Gast	
		US- 5,780,497	07-14-1998	Miller et al.	
		US- 5,842,476	12-01-1998	Wright et al.	
		US- 5,855,906	01-05-1999	McClay	
		US- 5,858,405	01-12-1999	Gast	
		US- 5,888,543	03-30-1999	Gast	
		US- 5,891,868	04-06-1999	Cummings et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO 98/56389 A1	12-17-1998	Rodriguez		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of 8

Complete if Known

Application Number	10/802,427
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Raymond J. Henley III
Attorney Docket Number	31162A

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,898,038	04-27-1999	Yallampalli et al.	
		US- 5,922,349	07-13-1999	Elliesen et al.	
		US- 6,028,064	02-22-2000	Rodriguez et al.	
		US- 6,034,074	03-07-2000	Rodriguez et al.	
		US- 6,310,054	10-30-2001	Rodriguez et al.	
		US- 6,319,911	11-20-2001	Rodriguez et al.	
		US- 6,407,082	06-18-2002	Rodriguez et al.	
		US- 6,444,658	09-03-2002	Rodriguez et al.	
		US- 6,511,970	01-28-2003	Rodriguez et al.	
		US- 6,765,002	07-20-2004	Rodriguez et al.	
		US- 6,977,250	12-20-2005	Rodriguez et al.	
		US- 7,053,074	05-30-06	Rodriguez et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ * Number ⁴ * Kind Code ⁵ (if known)				

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,427
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Raymond J. Henley III
Sheet 4	of 8	Attorney Docket Number	31162A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ARCHER, et al., A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 mg and Ethinyl Estradiol 20 mg, Contraception, (1997) 55:139-144	
		BAST, et al., Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, Chapter 321, 13th Ed., Isselbacher et al., (Eds.) pp. 1853-1858, McGraw-Hill, New York	
		BU, et al., Progesterone Induces Apoptosis and Up-Regulation of p53 Expression in Human Ovarian Carcinoma Cell Lines, Amer. Cancer Society, 1997, 79:1944-1950, China	
		CASAGRANDE, et al., "Incessant Ovulation" and Ovarian Cancer, The Lancet, July 28, 1979, pp. 170-172, Los Angeles, California	
		EVANGELOU, et al., Down-regulation of Transforming Growth Factor B receptors by androgen in ovarian cancer cells, Cancer Research, 2000, 60:929-935	
		FRANSESCHI, et al., Pooled Analysis of 3 European Case-Control Studies of Epithelial Ovarian Cancer: III. Oral Contraceptive Use, Int. J. Cancer, 1991, 49:61-65, Wiley-Liss	
		GREENE, et al., The Epidemiology of Ovarian Cancer, Seminars in Oncology, September 1984, pp. 209-225, Vol. 11, No. 3, USA	
		GRIMES, et al., Primary Prevention of Gynecologic Cancers, Am. J. Obstet. Gynecol., January 1995, pp. 227-235, San Francisco, California	
		GROSS, et al., The Estimated Effect of Oral Contraceptive Use on the Cumulative Risk of Epithelial Ovarian Cancer, OCs and Ovarian Cancer, 1994 pp. 419-424, Vol. 83, No. 3 USA	
		HAMMOND, Climacteric, Danforth's Obstetrics and Gynecology, 1994, pp. 771-790, Chapter 42, 7th Ed., Philadelphia	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/802,427		
		Filing Date	03/17/04		
		First Named Inventor	Rodriguez		
		Art Unit	1614		
		Examiner Name	Raymond J. Henley III		
Sheet	5	of	8	Attorney Docket Number	31162A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HICKEY, et al., Metabolic and Endocrinologic Effects of Steroidal Contraception, J. Sciarra Editor, 1996, pp. 1-14, Vol. 6, Chapter 24, Lippincott, Philadelphia	
		JORDAN, The Estrogenic Activity of Synthetic Progestins Used in Oral Contraceptives, Cancer, 1993, Vol. 71, No. 4, pp. 1501-1505	
		LEE, The Reduction in Risk of Ovarian Cancer Associated with Oral Contraceptive Use, 1987, New Engl. J. Med., 316:650-655	
		LEFKOWITZ, et al., Sunlight, Vitamin D, and Ovarian Cancer Mortality Rates in US Women, International Journal of Epidemiology, 1994, pp. 1133-1136, Vol 23, No 6, Great Britain	
		LIANG, et al., Risk of Breast, Uterine Corpus, and Ovarian Cancer in Women Receiving Medroxyprogesterone Injections, JAMA, 1983, pp. 2909-2912, Vol. 249, No. 21, USA	
		LINGEMAN, Etiology of Cancer of the Human Ovary: A Review, The Journal of the National Cancer Institute, December 1974, pp. 1603-1618, Vol. 53, No. 6	
		LOCKER, et al. Hormonal Therapy of breast cancer, Cancer Treatment Reviews, 1998, Vol. 24, pp. 221-240, W.B. Saunders Company Ltd.	
		LOCKSHIN, et al., The Biology of Cell Death and Its Relationship to Aging, Cellular Aging and Cell Death, 1996, pp. 167-180, Wiley-Liss Inc.	
		LOWE, et al., p53-Dependent Apoptosis in Tumor Progression and in Cancer Therapy, Cellular Aging and Cell Death, 1996, pp. 209-234, Wiley-Liss, Inc.	
		LUNDGREN, et al., Progestins in Breast Cancer treatment, ACTA Oncologica, 1992, Vol. 31, No. 7, pp. 709-722, Trondheim, Norway.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/802,427
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Raymond J. Henley III
Sheet 6	of 8	Attorney Docket Number	31162A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MAGOFFIN, et al., Estradoil-17B, insulin like growth factor-1, and lutienizing hormone inhibit secretion of transforming growth factor B by rat ovarian theca-interstitial	
		(continued from above) cells, Biology of Reproduction, 1995, 53, pp. 627-635	
		MUSS, et al., High-dose progestin therapy for metastatic breast cancer, Annals of Oncology, 1992, pp. S15-S20, Vol. 3, Netherlands	
		MUSS, Tamoxifen Versus High-Dose oral medroxyprogesterone Acetate as intital endocrine therapy for patients with metastatic breast cancer: A Peidmont,	
		(continued from above) Oncology Associate Study, Journal of Clinical Oncology, 1994, pp. 1630-1638, Vol. 12, No. 8	
		MUTCH, et al., Biology of Epithelial Ovarian Cancer, Clinical Obstetrics and Gynecology, 1994, pp. 406-422, Vol. 37, No. 2, L.B. Lippincott Co.	
		PFLEIDERER, The Problems of Prophylactic Chemotherapy, Second-look Surgery, and Maintenance of Remission in Therapy of Ovarian Cancer, Geburtshilfe und Frauenheiklunde,	
		(continued from above) 1976, pp. 132-139, Vol. 36, Germany	
		RAVIN, et al., Preformulation, Remington's Pharmaceutical Sciences, 1990, pp. 1435-1712, Chapters 75-92, Mack Publishing Co., Easton, PA	
		RODRIGUEZ, et al., Estrogen Replacement Therapy and Fatal Ovarian Cancer, American Journal of Epidemiology, 1995, pp. 828-835, Vol. 141, No. 9, USA	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,427
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Raymond J. Henley III
Sheet 7	of 8	Attorney Docket Number	31162A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ROSENBERG, et al., A Case-Control Study of Oral Contraceptive Use and Invasive Epithelial Ovarian Cancer, 1994, pp. 654-661, Vol. 139, No. 7, USA	
		ROSENBLATT, et al., High-dose and Low-dose Combined Oral Contraceptives: Protection Against Epithelial Ovarian Cancer and the Length of the Protective Effect,	
		(continued from above) Eur. J. Cancer, 1992, pp. 1872-1876, Vol. 28A, No. 11, Great Britian	
		ROSSING, et al., Ovarian Tumors in a Cohert of Infertile Women, The New England Journal of Medicine, 1994, pp. 771-776, Vol. 331, No. 12	
		RUDEL, Pharmacology of Contraceptive Steriods, Gynecology and Obstetrics, 1996, pp. 1871-1876, Vol. 6, Chapter 19	
		SCOTT, How to Induce Ovarian Cancer: And How Not To, British Medical Journal, September 29, 1984, pp. 781, 784, Vol. 289, Leeds	
		SPEROFF, et al., Steroid Contraception, Clinical Gynecologic Endocrinology and Infertility, 1989, Chapter 15, 4th Ed., pp. 461-498	
		STANFORD, et al. Epithelial Ovarian Cancer and Combined Oral Contraceptives, International Journal of Epidermiology, 1989, pp. 538-545, Vol. 18, No. 3, Great Britian	
		STANFORD, et al., Depot-Medroxyprogesterone Acetate (DMPA) and Risk of Epithelial Ovarian Cancer, Int. J. Cancer, 1991, pp. 191-195, Vol. 49, Wiley-Liss, Inc.	
		VOGEL, et al. Hormonal Approaches to Breast Cancer Treatment and Prevention: An Overview, Seminars in Oncology, 1996, pp. 2-9, Vol. 23, No. 4, Supp. 9	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/802,427
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Raymond J. Henley III
Sheet 8	of 8	Attorney Docket Number	31162A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		VOGEL, Update on the current use of hormonal as therapy in advanced breast cancer, use of hormonal in advanced breast cancer, Anti-Cancer Drugs, 2003, 14:265-273	
		WINGO, et al., Cancer Statistics 1995, A Cancer Journal for Clinicians, 1995, p. 30, Vol. 45, No. 1	
		WHITTEMORE, Characteristics Relating to Ovarian Cancer Risk: Implications for Prevention and Detection, Gynecologic Oncology, 1994, pp. S15-S19, Vol. 55, USA	
		WHITTEMORE, et al., Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies, Am. J. Epidem, 1992, pp. 1212-1220, Vol. 136, No 10	
		WU, et al., Personal and Environmental Characteristics Related to Epithelial Ovarian Cancer, Am. J. Epidem., 1988, pp. 1216-1227, Vol. 128, No. 6, USA	
		YOUNG, et al. Gynecologic Malignancies, Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, 13th Ed. pp. 1605-608	
		U.S. Patent Application Ser. No. 10/802,273 filed on March 17, 2004 (Inventor: Rodriguez, et al.)	
		Physicians' Desk Reference, 1996, pp. 1871-1876	
		CARLSTROM et al., Gynecologic and Obstetric Investigation, (1978), Vol. 9, No. 6, pp. 304-11 (Medine Abstract Only)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application-form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.H./